<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20240806021448&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20240806021448&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 06 Aug 2024 06:14:48 +0000</lastbuilddate>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102484/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):e151. doi: 10.1161/CIR.0000000000001280. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102484/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102484</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001280>10.1161/CIR.0000000000001280</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102484</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial</dc:title>
<dc:identifier>pmid:39102484</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001280</dc:identifier>
</item>
<item>
<title>Eicosapentanoic Acid Supplementation for Atherosclerotic Cardiovascular Disease Prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102483/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):435-438. doi: 10.1161/CIRCULATIONAHA.124.069881. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102483/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102483</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069881>10.1161/CIRCULATIONAHA.124.069881</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102483</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Vera Bittner</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Eicosapentanoic Acid Supplementation for Atherosclerotic Cardiovascular Disease Prevention</dc:title>
<dc:identifier>pmid:39102483</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069881</dc:identifier>
</item>
<item>
<title>Omega-3 Fatty Acids and Arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102482/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>The pro- and antiarrhythmic effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been extensively studied in preclinical and human trials. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit. Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):488-503. doi: 10.1161/CIRCULATIONAHA.123.065769. Epub 2024 Aug 5.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The pro- and antiarrhythmic effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been extensively studied in preclinical and human trials. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit. Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden cardiac death, but these findings have not been widely replicated, and the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to reduce arrhythmic death in combination, or as monotherapy, remains uncertain. The accumulated clinical evidence does not support supplementation of n-3 PUFA for postoperative AF or secondary prevention of AF. Several large, contemporary, randomized controlled trials of high-dose n-3 PUFA for primary or secondary cardiovascular prevention have demonstrated a small, significant, dose-dependent increased risk of incident AF compared with mineral oil or corn oil comparator. These findings were reproduced with both icosapent ethyl monotherapy and a mixed EPA+DHA formulation. The proarrhythmic mechanism of increased AF in contemporary cohorts exposed to high-dose n-3 PUFA is unknown. EPA and DHA and their metabolites have pleiotropic cardiometabolic and pro- and antiarrhythmic effects, including modification of the lipid raft microenvironment; alteration of cell membrane structure and fluidity; modulation of sodium, potassium, and calcium currents; and regulation of gene transcription, cell proliferation, and inflammation. Further characterization of the complex association between EPA, EPA+DHA, and DHA and AF is needed. Which formulations, dose ranges, and patient subgroups are at highest risk, remain unclear.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102482/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102482</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065769>10.1161/CIRCULATIONAHA.123.065769</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102482</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mason D Marcus</dc:creator>
<dc:creator>Mark S Link</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Omega-3 Fatty Acids and Arrhythmias</dc:title>
<dc:identifier>pmid:39102482</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065769</dc:identifier>
</item>
<item>
<title>Recognition of an Unusual Pattern in a Case of Narrow Complex Tachycardia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102481/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):506-508. doi: 10.1161/CIRCULATIONAHA.124.070584. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102481/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102481</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070584>10.1161/CIRCULATIONAHA.124.070584</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102481</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sudipta Mondal</dc:creator>
<dc:creator>Sreevilasam P Abhilash</dc:creator>
<dc:creator>Narayanan Namboodiri</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Recognition of an Unusual Pattern in a Case of Narrow Complex Tachycardia</dc:title>
<dc:identifier>pmid:39102481</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070584</dc:identifier>
</item>
<item>
<title>Retraction of: Abstract 18128: How Long Should We Tilt?: Challenging the 10-Minute Cutoff in the Diagnosis of Postural Tachycardia Syndrome (POTS)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):e152. doi: 10.1161/CIR.0000000000001279. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102480</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001279>10.1161/CIR.0000000000001279</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102480</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Retraction of: Abstract 18128: How Long Should We Tilt?: Challenging the 10-Minute Cutoff in the Diagnosis of Postural Tachycardia Syndrome (POTS)</dc:title>
<dc:identifier>pmid:39102480</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001279</dc:identifier>
</item>
<item>
<title>Response by Chatur et al to Letter Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102479/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):e107-e108. doi: 10.1161/CIRCULATIONAHA.124.069376. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102479/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102479</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069376>10.1161/CIRCULATIONAHA.124.069376</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102479</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Chatur et al to Letter Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial"</dc:title>
<dc:identifier>pmid:39102479</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069376</dc:identifier>
</item>
<item>
<title>Letter by Wang Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102478/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):e106. doi: 10.1161/CIRCULATIONAHA.123.068575. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102478/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102478</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068575>10.1161/CIRCULATIONAHA.123.068575</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102478</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Junwen Wang</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Wang Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial"</dc:title>
<dc:identifier>pmid:39102478</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068575</dc:identifier>
</item>
<item>
<title>Health Economics of Cardiovascular Disease in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):419-421. doi: 10.1161/CIRCULATIONAHA.124.068295. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102477</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068295>10.1161/CIRCULATIONAHA.124.068295</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102477</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Karen E Joynt Maddox</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Health Economics of Cardiovascular Disease in the United States</dc:title>
<dc:identifier>pmid:39102477</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068295</dc:identifier>
</item>
<item>
<title>Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):422-424. doi: 10.1161/CIRCULATIONAHA.124.070228. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39102475</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070228>10.1161/CIRCULATIONAHA.124.070228</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102475</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles</dc:title>
<dc:identifier>pmid:39102475</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070228</dc:identifier>
</item>
<item>
<title>Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39101625/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In ISCHEMIA, total plaque volume was associated with cardiovascular death or myocardial infarction. In this highly diseased, high-risk population, enhanced assessment of atherosclerotic burden using AI-QCT-derived measures of plaque volume and composition modestly improved event prediction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 5:ehae471. doi: 10.1093/eurheartj/ehae471. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The aim of this study was to determine the prognostic value of coronary computed tomography angiography (CCTA)-derived atherosclerotic plaque analysis in ISCHEMIA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Atherosclerosis imaging quantitative computed tomography (AI-QCT) was performed on all available baseline CCTAs to quantify plaque volume, composition, and distribution. Multivariable Cox regression was used to examine the association between baseline risk factors (age, sex, smoking, diabetes, hypertension, ejection fraction, prior coronary disease, estimated glomerular filtration rate, and statin use), number of diseased vessels, atherosclerotic plaque characteristics determined by AI-QCT, and a composite primary outcome of cardiovascular death or myocardial infarction over a median follow-up of 3.3 (interquartile range 2.2-4.4) years. The predictive value of plaque quantification over risk factors was compared in an area under the curve (AUC) analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Analysable CCTA data were available from 3711 participants (mean age 64 years, 21% female, 79% multivessel coronary artery disease). Amongst the AI-QCT variables, total plaque volume was most strongly associated with the primary outcome (adjusted hazard ratio 1.56, 95% confidence interval 1.25-1.97 per interquartile range increase [559 mm3]; P = .001). The addition of AI-QCT plaque quantification and characterization to baseline risk factors improved the model's predictive value for the primary outcome at 6 months (AUC 0.688 vs. 0.637; P = .006), at 2 years (AUC 0.660 vs. 0.617; P = .003), and at 4 years of follow-up (AUC 0.654 vs. 0.608; P = .002). The findings were similar for the other reported outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ISCHEMIA, total plaque volume was associated with cardiovascular death or myocardial infarction. In this highly diseased, high-risk population, enhanced assessment of atherosclerotic burden using AI-QCT-derived measures of plaque volume and composition modestly improved event prediction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39101625/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39101625</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae471>10.1093/eurheartj/ehae471</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39101625</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>James K Min</dc:creator>
<dc:creator>Rebecca Anthopolos</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>James P Earls</dc:creator>
<dc:creator>Tami Crabtree</dc:creator>
<dc:creator>G B John Mancini</dc:creator>
<dc:creator>Jonathon Leipsic</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:creator>Cameron J Hague</dc:creator>
<dc:creator>Sean M O'Brien</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Jeffrey S Berger</dc:creator>
<dc:creator>Robert Donnino</dc:creator>
<dc:creator>Mandeep S Sidhu</dc:creator>
<dc:creator>Jonathan D Newman</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:creator>Bernard R Chaitman</dc:creator>
<dc:creator>Peter H Stone</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Leslee J Shaw</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial</dc:title>
<dc:identifier>pmid:39101625</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae471</dc:identifier>
</item>
<item>
<title>Thrombus straddling a patent foramen ovale</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39101604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 5:ehae433. doi: 10.1093/eurheartj/ehae433. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39101604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39101604</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae433>10.1093/eurheartj/ehae433</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39101604</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Na Sun</dc:creator>
<dc:creator>Yan Cong</dc:creator>
<dc:creator>Bing-Xiang Wu</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thrombus straddling a patent foramen ovale</dc:title>
<dc:identifier>pmid:39101604</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae433</dc:identifier>
</item>
<item>
<title>Pulsus alternans under left ventricular assist device in a patient with dilated cardiomyopathy and LMNA mutation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39101600/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 5:ehae485. doi: 10.1093/eurheartj/ehae485. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39101600/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39101600</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae485>10.1093/eurheartj/ehae485</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39101600</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ryohei Sakai</dc:creator>
<dc:creator>Takeshi Kashimura</dc:creator>
<dc:creator>Takayuki Inomata</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulsus alternans under left ventricular assist device in a patient with dilated cardiomyopathy and LMNA mutation</dc:title>
<dc:identifier>pmid:39101600</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae485</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: colchicine after an acute ischaemic stroke shows no CHANCE of preventing recurrent events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39101474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 5:ehae498. doi: 10.1093/eurheartj/ehae498. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39101474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39101474</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae498>10.1093/eurheartj/ehae498</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39101474</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: colchicine after an acute ischaemic stroke shows no CHANCE of preventing recurrent events</dc:title>
<dc:identifier>pmid:39101474</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae498</dc:identifier>
</item>
<item>
<title>Long-Term Incidence of Bradycardia and Pacemaker Implantations Among Cross-Country Skiers: A Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39101218/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this study, male endurance skiers had a higher incidence of bradycardia and pacemaker implantations compared with nonskiers, a pattern not seen in women. Among male skiers, those who completed the most races and had the fastest finishing times had the highest incidence of bradycardia and pacemaker implantations. Within each group, mortality rates did not differ in relation to pacemaker status. These findings suggest that bradycardia associated with training leads to a higher risk...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 5. doi: 10.1161/CIRCULATIONAHA.123.068280. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Bradycardia is more common among well-trained athletes than in the general population, but the association with pacemaker implantations is less known. We investigated associations of endurance training with incidence of bradycardia and pacemaker implantations, including sex differences and long-term outcome, in a cohort of endurance trained individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All Swedish skiers who completed >;1 race in the cross-country skiing event Vasaloppet between 1989 and 2011 (n=209 108) and a sample of 532 290 nonskiers were followed until first event of bradycardia, pacemaker implantation, or death, depending on end point. The Swedish National Patient Register was used to obtain diagnoses. Cox regression was used to investigate associations of number of completed races and finishing time in Vasaloppet with incidence of bradycardia and pacemaker implantations. In addition, Cox regression was used to investigate associations of pacemaker implantations with death in skiers and nonskiers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Male skiers had a higher incidence of bradycardia (adjusted hazard ratio [aHR], 1.19 [95% CI, 1.05-1.34]) and pacemaker implantations (aHR, 1.17 [95% CI, 1.04-1.31]) compared with male nonskiers. Those who completed the most races and had the best performances exhibited the highest incidence. For female skiers in Vasaloppet, the incidence of bradycardia (aHR, 0.98 [95% CI, 0.75-1.30]) and pacemaker implantations (aHR, 0.98 [95% CI, 0.75-1.29]) was not different from that of female nonskiers. The indication for pacemaker differed between skiers and nonskiers, with sick sinus syndrome more common in the former and third-degree atrioventricular block in the latter. Skiers had lower overall mortality rates than nonskiers (aHR, 0.16 [95% CI, 0.15-0.17]). There were no differences in mortality rates by pacemaker status among skiers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this study, male endurance skiers had a higher incidence of bradycardia and pacemaker implantations compared with nonskiers, a pattern not seen in women. Among male skiers, those who completed the most races and had the fastest finishing times had the highest incidence of bradycardia and pacemaker implantations. Within each group, mortality rates did not differ in relation to pacemaker status. These findings suggest that bradycardia associated with training leads to a higher risk for pacemaker implantation without a detrimental effect on mortality risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39101218/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39101218</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068280>10.1161/CIRCULATIONAHA.123.068280</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39101218</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Niclas Svedberg</dc:creator>
<dc:creator>Johan Sundström</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:creator>Ulf Hållmarker</dc:creator>
<dc:creator>Kristina Hambraeus</dc:creator>
<dc:creator>Kasper Andersen</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-Term Incidence of Bradycardia and Pacemaker Implantations Among Cross-Country Skiers: A Cohort Study</dc:title>
<dc:identifier>pmid:39101218</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068280</dc:identifier>
</item>
<item>
<title>Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39101203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This multicenter, prospective study reports excellent procedural outcomes, 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era. Patients in the low-risk and intermediate-risk STS score categories had significantly better outcomes compared with those in the high-risk category. MViV is a reasonable therapy for the majority of patients with degenerated bioprosthetic mitral valves, who are anatomical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 5. doi: 10.1161/CIRCULATIONAHA.124.068847. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Previous transcatheter valve therapy registry analyses of transcatheter mitral valve in valve (MViV) replacement of degenerated bioprosthesis reported early experience in the United States. Given recent increases in transseptal MViV volumes and introduction of the SAPIEN 3 Ultra valve, it is important to determine contemporary outcomes for patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV replacement.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy Registry was used to extract data for all patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV from 2015 to September 2022. Primary efficacy outcome was 1-year all-cause mortality. Secondary end points included 30-day mortality, functional class, quality of life, and mitral valve performance. Primary safety outcomes were device success and in-hospital complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 4243 patients with a mean STS score of 9.2±7.7 underwent transseptal MViV at 455 sites. The rate of Mitral Valve Academic Research Consortium technical (96.6%) success was high, and procedural complications were low. All-cause in-hospital, 30-day, and 1-year mortality rates were 3.2%, 4.3%, and 13.4%, respectively. Significant improvements in New York Heart Association class (New York Heart Association I/II, 18% to 87%) and quality of life (Kansas City Cardiomyopathy Questionnaire score, 38 to 78) were noted at 1 year (<i>P</i>&lt;0.0001 for both) after MViV. Upon stratifying by STS scores, it was observed that the low-risk group (STS&lt;4) had a significantly lower in-hospital mortality rate of 0.4%, whereas the intermediate-risk group (STS, 4-8) had an in-hospital mortality rate of 1.9%. From 2015 to 2022, the number of transseptal MViV cases/year increased significantly, whereas procedure times, length of stay, and intensive care unit hours shortened significantly. At the same time, there was a significant trend toward reduced in-hospital (<i>P</i>=0.0005), 30-day (<i>P</i>=0.004), and 1-year mortality rates (<i>P</i>=0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This multicenter, prospective study reports excellent procedural outcomes, 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era. Patients in the low-risk and intermediate-risk STS score categories had significantly better outcomes compared with those in the high-risk category. MViV is a reasonable therapy for the majority of patients with degenerated bioprosthetic mitral valves, who are anatomical candidates.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39101203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39101203</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068847>10.1161/CIRCULATIONAHA.124.068847</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39101203</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Kashish Goel</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:creator>Samir Kapadia</dc:creator>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>Ashish Shah</dc:creator>
<dc:creator>Colin Barker</dc:creator>
<dc:creator>Ke Xu</dc:creator>
<dc:creator>Abhijeet Dhoble</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Charanjit S Rihal</dc:creator>
<dc:creator>Amr E Abbas</dc:creator>
<dc:creator>Mayra Guerrero</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States</dc:title>
<dc:identifier>pmid:39101203</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068847</dc:identifier>
</item>
<item>
<title>Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39101201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HFpEF, treatment with Dapagliflozin improved systemic arterial compliance and venous capacitance during exercise, while reducing aortic characteristic impedance, suggesting a reduction in arterial wall stiffness. These vascular effects may partially explain the clinical benefits with sodium-glucose cotransporter-2 inhibitors in HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 5. doi: 10.1161/CIRCULATIONAHA.124.068788. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis that Dapagliflozin would improve systemic arterial compliance and venous capacitance during exercise in patients with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this secondary analysis from the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial, 37 patients with HFpEF (mean age 68 ± 9 years, women 65%) underwent invasive hemodynamic exercise testing with simultaneous echocardiography at baseline and following treatment for 24 weeks with Dapagliflozin or placebo. Radial artery pressure (BP) was measured continuously using a fluid-filled catheter with transformation to aortic pressure, central hemodynamics were measured using high-fidelity micromanometers, and stressed blood volume was estimated from hemodynamic indices fit to a comprehensive cardiovascular model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There was no statistically significant effect of Dapagliflozin on resting BP, but Dapagliflozin reduced systolic BP during peak exercise (estimated treatment difference [ETD], -18.8 mm Hg [95% CI, -33.9 to -3.7] <i>P</i>=0.016). Reduction in BP was related to improved exertional total arterial compliance (ETD, 0.06 mL/mm Hg/m<sup>2</sup> [95% CI, 0.003-0.11] <i>P</i>=0.039) and aortic root characteristic impedance (ETD, -2.6 mm Hg/mL*sec [95% CI: -5.1 to -0.03] <i>P</i>=0.048), with no significant effect on systemic vascular resistance. Dapagliflozin reduced estimated stressed blood volume at rest and during peak exercise (ETD, -292 mm Hg [95% CI, -530 to -53] <i>P</i>=0.018), and improved venous capacitance evidenced by a decline in ratio of estimated stressed blood volume to total blood volume (ETD, -7.3% [95% CI, -13.3 to -1.3] <i>P</i>=0.020). Each of these effects of Dapagliflozin at peak exercise were also observed during matched 20W exercise intensity. Improvements in total arterial compliance and estimated stressed blood volume were correlated with decreases in body weight, and reduction in systolic BP with treatment was correlated with the change in estimated stressed blood volume during exercise (r=0.40, <i>P</i>=0.019). Decreases in BP were correlated with reduction in pulmonary capillary wedge pressure during exercise (r=0.56, <i>P</i>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFpEF, treatment with Dapagliflozin improved systemic arterial compliance and venous capacitance during exercise, while reducing aortic characteristic impedance, suggesting a reduction in arterial wall stiffness. These vascular effects may partially explain the clinical benefits with sodium-glucose cotransporter-2 inhibitors in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04730947.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39101201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39101201</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068788>10.1161/CIRCULATIONAHA.124.068788</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39101201</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Atsushi Tada</dc:creator>
<dc:creator>Daniel Burkhoff</dc:creator>
<dc:creator>Jwan A Naser</dc:creator>
<dc:creator>Tomonari Harada</dc:creator>
<dc:creator>Bianca Pourmussa</dc:creator>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:creator>Michael D Jensen</dc:creator>
<dc:creator>Rickey Carter</dc:creator>
<dc:creator>Ryan T Demmer</dc:creator>
<dc:creator>Jeffrey Testani</dc:creator>
<dc:creator>Julio A Chirinos</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial</dc:title>
<dc:identifier>pmid:39101201</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068788</dc:identifier>
</item>
<item>
<title>Neutrophil trapping and nexocytosis, mast cell-mediated processes for inflammatory signal relay</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39096902/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>Neutrophils are sentinel immune cells with essential roles for antimicrobial defense. Most of our knowledge on neutrophil tissue navigation derived from wounding and infection models, whereas allergic conditions remained largely neglected. Here, we analyzed allergen-challenged mouse tissues and discovered that degranulating mast cells (MCs) trap living neutrophils inside them. MCs release the attractant leukotriene B4 to re-route neutrophils toward them, thus exploiting a chemotactic system that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 27:S0092-8674(24)00774-8. doi: 10.1016/j.cell.2024.07.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Neutrophils are sentinel immune cells with essential roles for antimicrobial defense. Most of our knowledge on neutrophil tissue navigation derived from wounding and infection models, whereas allergic conditions remained largely neglected. Here, we analyzed allergen-challenged mouse tissues and discovered that degranulating mast cells (MCs) trap living neutrophils inside them. MCs release the attractant leukotriene B4 to re-route neutrophils toward them, thus exploiting a chemotactic system that neutrophils normally use for intercellular communication. After MC intracellular trap (MIT) formation, neutrophils die, but their undigested material remains inside MC vacuoles over days. MCs benefit from MIT formation, increasing their functional and metabolic fitness. Additionally, they are more pro-inflammatory and can exocytose active neutrophilic compounds with a time delay (nexocytosis), eliciting a type 1 interferon response in surrounding macrophages. Together, our study highlights neutrophil trapping and nexocytosis as MC-mediated processes, which may relay neutrophilic features over the course of chronic allergic inflammation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39096902/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39096902</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.014>10.1016/j.cell.2024.07.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39096902</guid>
<pubDate>Sat, 03 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Mihlan</dc:creator>
<dc:creator>Stefanie Wissmann</dc:creator>
<dc:creator>Alina Gavrilov</dc:creator>
<dc:creator>Lukas Kaltenbach</dc:creator>
<dc:creator>Marie Britz</dc:creator>
<dc:creator>Kristin Franke</dc:creator>
<dc:creator>Barbara Hummel</dc:creator>
<dc:creator>Andrea Imle</dc:creator>
<dc:creator>Ryo Suzuki</dc:creator>
<dc:creator>Manuel Stecher</dc:creator>
<dc:creator>Katharina M Glaser</dc:creator>
<dc:creator>Axel Lorentz</dc:creator>
<dc:creator>Peter Carmeliet</dc:creator>
<dc:creator>Takehiko Yokomizo</dc:creator>
<dc:creator>Ingo Hilgendorf</dc:creator>
<dc:creator>Ritwick Sawarkar</dc:creator>
<dc:creator>Alba Diz-Muñoz</dc:creator>
<dc:creator>Joerg M Buescher</dc:creator>
<dc:creator>Gerhard Mittler</dc:creator>
<dc:creator>Marcus Maurer</dc:creator>
<dc:creator>Karoline Krause</dc:creator>
<dc:creator>Magda Babina</dc:creator>
<dc:creator>Luise Erpenbeck</dc:creator>
<dc:creator>Marcus Frank</dc:creator>
<dc:creator>Angelika S Rambold</dc:creator>
<dc:creator>Tim Lämmermann</dc:creator>
<dc:date>2024-08-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Neutrophil trapping and nexocytosis, mast cell-mediated processes for inflammatory signal relay</dc:title>
<dc:identifier>pmid:39096902</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.014</dc:identifier>
</item>
<item>
<title>Spotlight on hot topics: subclinical atrial fibrillation, risk stratification of channelopathies, and cardioprotection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39096162/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 3;45(29):2579-2583. doi: 10.1093/eurheartj/ehae477.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39096162/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39096162</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae477>10.1093/eurheartj/ehae477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39096162</guid>
<pubDate>Sat, 03 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-08-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Spotlight on hot topics: subclinical atrial fibrillation, risk stratification of channelopathies, and cardioprotection</dc:title>
<dc:identifier>pmid:39096162</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae477</dc:identifier>
</item>
<item>
<title>A replisome-associated histone H3-H4 chaperone required for epigenetic inheritance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39094570/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>Faithful transfer of parental histones to newly replicated daughter DNA strands is critical for inheritance of epigenetic states. Although replication proteins that facilitate parental histone transfer have been identified, how intact histone H3-H4 tetramers travel from the front to the back of the replication fork remains unknown. Here, we use AlphaFold-Multimer structural predictions combined with biochemical and genetic approaches to identify the Mrc1/CLASPIN subunit of the replisome as a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25:S0092-8674(24)00766-9. doi: 10.1016/j.cell.2024.07.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Faithful transfer of parental histones to newly replicated daughter DNA strands is critical for inheritance of epigenetic states. Although replication proteins that facilitate parental histone transfer have been identified, how intact histone H3-H4 tetramers travel from the front to the back of the replication fork remains unknown. Here, we use AlphaFold-Multimer structural predictions combined with biochemical and genetic approaches to identify the Mrc1/CLASPIN subunit of the replisome as a histone chaperone. Mrc1 contains a conserved histone-binding domain that forms a brace around the H3-H4 tetramer mimicking nucleosomal DNA and H2A-H2B histones, is required for heterochromatin inheritance, and promotes parental histone recycling during replication. We further identify binding sites for the FACT histone chaperone in Swi1/TIMELESS and DNA polymerase α that are required for heterochromatin inheritance. We propose that Mrc1, in concert with FACT acting as a mobile co-chaperone, coordinates the distribution of parental histones to newly replicated DNA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39094570/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39094570</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.006>10.1016/j.cell.2024.07.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39094570</guid>
<pubDate>Fri, 02 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Juntao Yu</dc:creator>
<dc:creator>Yujie Zhang</dc:creator>
<dc:creator>Yimeng Fang</dc:creator>
<dc:creator>Joao A Paulo</dc:creator>
<dc:creator>Dadmehr Yaghoubi</dc:creator>
<dc:creator>Xu Hua</dc:creator>
<dc:creator>Gergana Shipkovenska</dc:creator>
<dc:creator>Takenori Toda</dc:creator>
<dc:creator>Zhiguo Zhang</dc:creator>
<dc:creator>Steven P Gygi</dc:creator>
<dc:creator>Songtao Jia</dc:creator>
<dc:creator>Qing Li</dc:creator>
<dc:creator>Danesh Moazed</dc:creator>
<dc:date>2024-08-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A replisome-associated histone H3-H4 chaperone required for epigenetic inheritance</dc:title>
<dc:identifier>pmid:39094570</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.006</dc:identifier>
</item>
<item>
<title>The fork protection complex promotes parental histone recycling and epigenetic memory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39094569/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>The inheritance of parental histones across the replication fork is thought to mediate epigenetic memory. Here, we reveal that fission yeast Mrc1 (CLASPIN in humans) binds H3-H4 tetramers and operates as a central coordinator of symmetric parental histone inheritance. Mrc1 mutants in a key connector domain disrupted segregation of parental histones to the lagging strand comparable to Mcm2 histone-binding mutants. Both mutants showed clonal and asymmetric loss of H3K9me-mediated gene silencing....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 26:S0092-8674(24)00777-3. doi: 10.1016/j.cell.2024.07.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The inheritance of parental histones across the replication fork is thought to mediate epigenetic memory. Here, we reveal that fission yeast Mrc1 (CLASPIN in humans) binds H3-H4 tetramers and operates as a central coordinator of symmetric parental histone inheritance. Mrc1 mutants in a key connector domain disrupted segregation of parental histones to the lagging strand comparable to Mcm2 histone-binding mutants. Both mutants showed clonal and asymmetric loss of H3K9me-mediated gene silencing. AlphaFold predicted co-chaperoning of H3-H4 tetramers by Mrc1 and Mcm2, with the Mrc1 connector domain bridging histone and Mcm2 binding. Biochemical and functional analysis validated this model and revealed a duality in Mrc1 function: disabling histone binding in the connector domain disrupted lagging-strand recycling while another histone-binding mutation impaired leading strand recycling. We propose that Mrc1 toggles histones between the lagging and leading strand recycling pathways, in part by intra-replisome co-chaperoning, to ensure epigenetic transmission to both daughter cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39094569/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39094569</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.017>10.1016/j.cell.2024.07.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39094569</guid>
<pubDate>Fri, 02 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sebastian Jespersen Charlton</dc:creator>
<dc:creator>Valentin Flury</dc:creator>
<dc:creator>Yutaka Kanoh</dc:creator>
<dc:creator>Aitana Victoria Genzor</dc:creator>
<dc:creator>Leonie Kollenstart</dc:creator>
<dc:creator>Wantong Ao</dc:creator>
<dc:creator>Peter Brøgger</dc:creator>
<dc:creator>Melanie Bianca Weisser</dc:creator>
<dc:creator>Marek Adamus</dc:creator>
<dc:creator>Nicolas Alcaraz</dc:creator>
<dc:creator>Charlotte M Delvaux de Fenffe</dc:creator>
<dc:creator>Francesca Mattiroli</dc:creator>
<dc:creator>Guillermo Montoya</dc:creator>
<dc:creator>Hisao Masai</dc:creator>
<dc:creator>Anja Groth</dc:creator>
<dc:creator>Geneviève Thon</dc:creator>
<dc:date>2024-08-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The fork protection complex promotes parental histone recycling and epigenetic memory</dc:title>
<dc:identifier>pmid:39094569</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.017</dc:identifier>
</item>
<item>
<title>Activation of the helper NRC4 immune receptor forms a hexameric resistosome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39094568/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240806021448&amp;v=2.18.0.post9+e462414
      <description>Innate immune responses to microbial pathogens are regulated by intracellular receptors known as nucleotide-binding leucine-rich repeat receptors (NLRs) in both the plant and animal kingdoms. Across plant innate immune systems, "helper" NLRs (hNLRs) work in coordination with "sensor" NLRs (sNLRs) to modulate disease resistance signaling pathways. Activation mechanisms of hNLRs based on structures are unknown. Our research reveals that the hNLR, known as NLR required for cell death 4 (NRC4),...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 30:S0092-8674(24)00773-6. doi: 10.1016/j.cell.2024.07.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Innate immune responses to microbial pathogens are regulated by intracellular receptors known as nucleotide-binding leucine-rich repeat receptors (NLRs) in both the plant and animal kingdoms. Across plant innate immune systems, "helper" NLRs (hNLRs) work in coordination with "sensor" NLRs (sNLRs) to modulate disease resistance signaling pathways. Activation mechanisms of hNLRs based on structures are unknown. Our research reveals that the hNLR, known as NLR required for cell death 4 (NRC4), assembles into a hexameric resistosome upon activation by the sNLR Bs2 and the pathogenic effector AvrBs2. This conformational change triggers immune responses by facilitating the influx of calcium ions (Ca<sup>2+</sup>) into the cytosol. The activation mimic alleles of NRC2, NRC3, or NRC4 alone did not induce Ca<sup>2+</sup> influx and cell death in animal cells, suggesting that unknown plant-specific factors regulate NRCs' activation in plants. These findings significantly advance our understanding of the regulatory mechanisms governing plant immune responses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39094568/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240806021448&v=2.18.0.post9+e462414">39094568</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.013>10.1016/j.cell.2024.07.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39094568</guid>
<pubDate>Fri, 02 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Furong Liu</dc:creator>
<dc:creator>Zhenlin Yang</dc:creator>
<dc:creator>Chao Wang</dc:creator>
<dc:creator>Zhang You</dc:creator>
<dc:creator>Raoul Martin</dc:creator>
<dc:creator>Wenjie Qiao</dc:creator>
<dc:creator>Jian Huang</dc:creator>
<dc:creator>Pierre Jacob</dc:creator>
<dc:creator>Jeffery L Dangl</dc:creator>
<dc:creator>Jan E Carette</dc:creator>
<dc:creator>Sheng Luan</dc:creator>
<dc:creator>Eva Nogales</dc:creator>
<dc:creator>Brian J Staskawicz</dc:creator>
<dc:date>2024-08-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Activation of the helper NRC4 immune receptor forms a hexameric resistosome</dc:title>
<dc:identifier>pmid:39094568</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.013</dc:identifier>
</item>





























</channel>
</rss>